08:00 , Feb 29, 2016 |  BC Week In Review  |  Company News

Pfizer gastrointestinal news

Pfizer will pay $784.6 million to resolve allegations regarding Medicaid rebate claims for its gastrointestinal drug Protonix pantoprazole, a proton pump inhibitor (PPI). Specifically, the deal settles cases in the U.S. District Court for the...
07:00 , Jun 17, 2013 |  BC Week In Review  |  Company News

Sun Pharmaceutical, Teva, Pfizer, Takeda gastrointestinal news

Teva and Sun will pay $2.2 billion to Pfizer and Takeda to settle litigation related to the validity of a patent owned by Takeda's Nycomed company covering gastrointestinal drug Protonix pantoprazole. Sun and Teva admitted...
08:00 , Feb 13, 2012 |  BC Week In Review  |  Clinical News

AcipHex rabeprazole regulatory update

FDA issued a safety communication to warn that prescription and OTC proton pump inhibitors (PPI) may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD). The agency said a diagnosis of CDAD should...
07:00 , Aug 29, 2011 |  BC Week In Review  |  Company News

Pfizer transplant, gastrointestinal news

Pfizer disclosed in an SEC filing that it voluntarily provided the U.S. Department of Justice and the SEC with information about potentially improper payments made by Pfizer and its Wyeth subsidiary in connection with certain...
07:00 , Aug 8, 2011 |  BioCentury  |  Finance

Value vaporization

Investors slashed more than $3 billion off the combined market caps of partners Active Biotech AB (SSE:ACTI) and Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) last week after laquinimod missed the primary endpoint in the Phase III...
08:00 , Mar 7, 2011 |  BC Week In Review  |  Clinical News

AciPhex rabeprazole regulatory update

FDA issued an alert to healthcare professionals that the use of prescription and OTC proton pump inhibitors (PPI) may cause hypomagnesemia if taken for prolonged periods of time, in most cases longer than 1 year....
07:00 , Oct 4, 2010 |  BC Week In Review  |  Clinical News

Nexium esomeprazole magnesium regulatory update

FDA's Gastrointestinal Drug Advisory Committee will meet on Nov. 5 to discuss proton pump inhibitors (PPIs) to treat gastroesophageal reflux disease (GERD) in patients less than 1 year of age. The panel will also discuss...
07:00 , Oct 4, 2010 |  BC Week In Review  |  Clinical News

Prevacid lansoprazole regulatory update

FDA's Gastrointestinal Drug Advisory Committee will meet on Nov. 5 to discuss proton pump inhibitors (PPIs) to treat gastroesophageal reflux disease (GERD) in patients less than 1 year of age. The panel will also discuss...
07:00 , Oct 4, 2010 |  BC Week In Review  |  Clinical News

Protonix pantoprazole regulatory update

FDA's Gastrointestinal Drug Advisory Committee will meet on Nov. 5 to discuss proton pump inhibitors (PPIs) to treat gastroesophageal reflux disease (GERD) in patients less than 1 year of age. The panel will also discuss...
07:00 , Jul 26, 2010 |  BC Week In Review  |  Company News

Teva, UCB, Nycomed, Pfizer, Sun Pharmaceutical gastrointestinal news

A judge in the U.S. District Court for the District of New Jersey confirmed an April jury verdict that upheld the validity of Nycomed's patent covering gastrointestinal drug Protonix pantoprazole. The jury found that U.S....